5-氟尿嘧啶 (5-FU) 是一种抗肿瘤药物，因其生物利用度低和细胞渗透有限而闻名，通常会对健康细胞产生不利影响。因此，寻找能够增强生物利用度、实现控制释放并减轻不利影响的载体至关重要。该研究的重点是将 5-FU 封装在大豆卵磷脂囊泡 (SLV) 中，并评估其对载体特性和功能的影响。结果表明，加入 5-FU 不会影响 SLV 的大小或多分散性，甚至在冻干后也是如此。从 SLV 中释放 5-FU 需要破坏系统而不是自发释放，使用方波伏安法测定的封装效率约为 43%。对结直肠癌细胞的细胞毒性测定显示，基于 SLV 的递送具有显着功效，超过了游离药物溶液的效果，72 小时后细胞活力为 45%，而细胞活力为 73%。该研究通过创建一种生物相容性纳米载体来实现高效药物输送，解决了 5-FU 有限的生物利用度问题，并强调 SLV 由于持续的抗增殖作用和改善的细胞摄取而有望用于靶向癌症治疗。该研究强调了定制药物输送系统在增强治疗效果方面的重要性，并建议 SLV/5-FU 制剂作为癌症治疗策略的潜在进步。

5-Fluorouracil (5-FU) is an antineoplastic agent known for its low bioavailability and limited cellular penetration, often resulting in adverse effects on healthy cells. Thus, finding vehicles that enhance bioavailability, enable controlled release, and mitigate adverse effects is crucial. The study focuses on encapsulating 5-FU within soy lecithin vesicles (SLVs) and assessing its impact on the carrier's properties and functionality. Results show that incorporating 5-FU does not affect SLVs' size or polydispersity, even postlyophilization. Liberation of 5-FU from SLVs requires system disruption rather than spontaneous release, with an encapsulation efficiency of approximately 43% determined using Square Wave Voltammetry. Cytotoxicity assays on colorectal cancer cells reveal SLV-based delivery's significant efficacy, surpassing free drug solution effects with 45% cell viability after 72 h vs 73% viability. The research addresses 5-FU's limited bioavailability by creating a biocompatible nanocarrier for efficient drug delivery, highlighting SLVs as promising for targeted cancer therapy due to sustained antiproliferative effects and improved cellular uptake. The study underscores the importance of tailored drug delivery systems in enhancing therapeutic outcomes and suggests SLV/5-FU formulations as a potential advancement in cancer treatment strategies.